

**Adlyxin (lixisenatide)**  
**Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE  FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_\_\_

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [PRIMETHERAPEUTICS.COM/NOPP](http://PRIMETHERAPEUTICS.COM/NOPP)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_  
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: \_\_\_\_\_

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

*Continued on next page.*

**Adlyxin (lixisenatide)**  
**Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit  
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

**1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?**  YES (if yes, complete below)  NO

<b>MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):</b>  	<b>DURATION OF THERAPY (SPECIFY DATES):</b>  	<b>RESPONSE/REASON FOR FAILURE/ALLERGY:</b>  
---	---	---

**2. LIST DIAGNOSES:** **ICD-10:**

<input type="checkbox"/> Type II diabetes <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____ 	
--	--

**3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.**

**Lab Values:**  
 Was the patient's most recent HbA1c in the past 6 months or prior to starting the requested medication 7.0% or greater?  Yes  No  
*Documentation of HbA1c level required.*

Is the patient's estimated glomerular filtration rate (GFR) less than or equal to 45 mL/min/1.73 m<sup>2</sup>?  Yes  No  
*Documentation of GFR required.*

Does the patient currently have a serum creatinine level exceeding 1.8 mg/dL or an estimated GFR less than 30 mL/min/1.73 m<sup>2</sup>?  Yes  No  
*Documentation required.*

**Clinical information:**  
 Has the patient tried or is the patient currently taking metformin?  Yes  No

Has treatment with metformin been avoided due to lactic acidosis or elevated liver enzymes?  Yes  No

Does the patient have advanced liver disease with at least one of the following?  Yes  No  
 If yes, please select:  
 Ascites  
 Cirrhosis  
 Hepatic encephalopathy  
 Portal hypertension

Is the patient currently taking any of the following medications?  Yes  No  
 If yes, please select:  
 Janumet/Janumet XR (sitagliptin/metformin)  
 Januvia (sitagliptin)  
 Jentadueto/Jentadueto XR (linagliptin/metformin)  
 Kazano (alogliptin/metformin)  Kombiglyze XR (saxagliptin/metformin)  
 Nesina (alogliptin)  
 Onglyza (saxagliptin)



**Adlyxin (lixisenatide)**  
**Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

- Oseni (alogliptin/pioglitazone)
- Tradjenta (linagliptin)
- Glyxambi (empagliflozin/linagliptin)
- Seglujan (ertugliflozin/sitagliptin)
- Qtern (dapagloflozin/saxagliptin)

If the patient is taking any of the above medications, will concomitant therapy with those medications be discontinued?  Yes  No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

---

---

**Please note:** Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature or Electronic I.D. Verification:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO: 800-424-7640**

**MAIL REQUESTS TO:** Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201

P.O. Box 64811

St. Paul, MN 55164-0811